Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland

AIM OF THE STUDY: Erlotinib and gefitinib are reversible EGFR-TKI administered orally. Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. We analyze efficacy of treatment with erlotinib in patients suff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kowalski, Dariusz M., Krzakowski, Maciej, Ramlau, Rodryg, Jaskiewicz, Piotr, Janowicz-Żebrowska, Anna
Format: Artigo
Sprache:Inglês
Veröffentlicht: Termedia Publishing House 2012
Schlagworte:
Original Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3687401/
https://ncbi.nlm.nih.gov/pubmed/23788872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2012.28798
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge